 ce with the guidelines is available on https://www.ascelia.com/corporate -
governance/general -meeting/. No r emuneration has been reclaimed. 
 
In addition to such remuneration covered by the remuneration guidelines, the general meetings of the company have 
resolved to implement long -term share -related incentive programs . 
 
 
Table 1 – Total remuneration of the CEO in 2024 (TSEK) 
 
* Short -term variable remuneration refers to the 202 4 target achievement . 
**The amount for share -related incentive programs reflects the value of allotted ordinary shares in 202 4. The value of unpaid active share -based incentive programs is not included. 
 Name of 
director 
(position) Fixed remuneration Variable remuneration 
Extraordinary 
items Pension 
expense incl. 
insurance Total 
remuneration Proportion of 
fixed and 
variable 
remuneration Base salary Other 
benefits One-year Multi- year 
 Salary + 
holiday pay Company 
car etc. Short term 
variable pay * Share -related 
incentive 
pro ive up to 5 performance s hares 
(“Performance Shares”) for each Saving Share. Receipt of both Matching Shares and Performance Shares are conditional 
upon the fulfilment of the following conditions: 
(a) that the participant has retained all Saving Shares during the period from the expiration of the relevant investment 
period to the end of the relevant Saving Period ( 30 September 2025 for LTI 2022, 30 September 2026 for LTI 2023 
and 30 September 2027 for LTI 2024): 
(b) that the participant has continued to be employed by the company throughout the relevant Saving Period; and 
(c) the r eceipt of Performance Shares is further conditional upon that the requirement related to the development of 
the company’s share price from the date of the annual general meeting when the programs were decided (5 May 2022 
for LTI 2022, 4 May 2023 for LTI 2023 and 6 May 2024 for LTI 2024) to the end of the Saving Period . 
 
During 202 4, the share saving program LTI 20 21 expired. In November 202 4 d. In November 202 4, 26,310 Matching Shares, corresponding 
to an equal number of ordinary shares , were allotted to the participants in LTI 2021 , of which 11, 100 were allotted to 
the CEO. The share price targets set for the program were not met, with the result that no Performance Shares were 
allotted in relation to LTI 20 21. 
 The CEO has invested 22,500 Saving Shares in LTI 2022 , 31,000 Saving Shares in LTI 2023 and 54,000 Saving Shares 
in LTI 2024. For the company , in the active programs, 326,806 Saving Shares have been acquired by the participants 
(48,510 in LTI 2022 , 96,990 in LTI 2023 and 181,306 in LTI 2024 ). The recalculation due to the rights issue of units 
completed during 2024, enti tles the holder of Saving Shares to receive 1.11 Matching Shares . The number of shares 
acquired has been revised in relation to personnel no longer employed. 
 
Table 2 – Share option programs (CEO) 
 
* The value of the vested options in 202 4 at the vesting date 31 October 202 4 024-12-31 3.30 SEK 
per share 360,000 - 360,000* - - - 
TOTAL 360,000 - 360,000 - - -

Table 3 – Share saving program s (CEO) 
 
Name of 
director 
(position) Information regarding the reported financial year 
Main conditions Opening 
balance During the year Closing balance 
Specification 
of program Performance 
period Award date Vesting 
period 
(Saving 
Period) End of 
retention 
period Number of 
Saving 
Shares at 
start of 
year Saving 
Shares 
acquired Allotted 
Matching 
Shares ** Shares subject 
to a 
performance 
condition* ** Shares 
unvested at 
year end* Shares 
subject to a 
retention 
period 
LTI 2021 5 May 2021 - 
30 Sep 2024 2021-05-05 May 2021 - 
Sep 2024 2024-09-30 10,000 - 11,100 - - - 
LTI 2022 5 May 2022 - 
30 Sep 2025 2022-05-05 May 2022 - 
Sep 2025 2025-09-30 22,500 - - 22,500 22,500 - 
LTI 2023 4 May 2023 – 
30 Sep 2026 2023-05-04 May 2023 
– Sep 2026 2026-09-30 31,000 - - 31,000 31,000 - 
LTI 2024 6 May 2024 – 
30 Sep 2027 2024-05-06 May 2024 
– Sep 2027 2027-0 4 
– Sep 2027 2027-09-30 - 54,000 - 54,000 54,000 - 
TOTAL 63,500 54,000 11,100 107,500 107,500 - 
* The total estimated costs throughout the vesting period 2022-2027 for all active share saving programs amount to 1.8 M SEK. The calculation of costs is based on the generally 
accepted modelling technique Monte Carlo for simulation of future share prices. 
** In September 2024, the Shares in all LTI programs were recalculated due to the rights issue of units completed during 2024 in accordance with the terms of the programs. 
After recalculation, each saving share entitled to 1.11 M atching Shares . The value of the 11,100 allotted Matching Shares, corresponding to an equal number of ordinary shares, 
amounts to 32 TSEK in 2024 . 
*** The performance condition implies that the participant has not terminated the empl oyment as of the date when the vesting occurs. 
 
 
 
APPLICATION OF PERFORMANCE CRITERIA 
The performance criteria for the CEO’s variable remuneration have been selected to ave been selected to support the company’s strategy 
and long- term goals. The performance criteria have been composed of both operational and financial criteria that 
overall support the long -term strategic direction and value creation of Ascelia Pharma. 
 
Table 4 – Outcome of the CEO ’s variable remuneration for 2024* 
In 202 4, the CEO was awarded 752 T SEK in variable remuneration based on fulfilment of performance criteria *. The 
weighting of each performance criteria and their individual degree of fulfilment are found in the table below. 
 
Performance criteria Relative weighting Degree of fulfilment * 
Development 60% 87% 
Financing and corporate 40% 
* Outcome of the CEO's variable remuneration refers to the 202 4 target fulfilment . 
 
COMPARATIVE INFORMATION ON THE CHANGE OF REMUNERATION AND COMPANY PERFORMANCE 
 
Table 5 – Remuneration and company performance in 2024 and 2023 
 
 2024 2023 
Remuneration to Magnus Corfitzen, CEO 3.9 MSEK* 3.8 MSEK* 
Operating Results for t